Slovenia
Industry
BMI View: Krka has posted moderate revenue growth for H112, in line with its expectations for the year. Operating profit and reported profit were down, with higher distribution expenses...
2012-08-03Industry
BMI View: Our view that Slovenia's drug market is one of the most stable in the region remains in place despite the fact that at the start of 2012 the government introduced new measures...
2012-04-16Industry
BMI View: Krka's dual listing on the Warsaw Stock Exchange (WSE) will improve the liquidity of the stock by increasing its international exposure and visibility to investors, both of...
2012-04-10Industry
BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)...
2012-04-05Industry
BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients...
2012-03-12Industry
BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients...
2011-11-02Industry
BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets...
2011-10-12Industry
BMI View: Our equity view of Slovenian company Krka remains neutral, but with some upside potential since our previous analysis. Despite the company's exposure to high-growth pharmaceutical...
2011-07-08
